Inhibrx announces positive interim results from HexAgon trial

​Inhibrx Biosciences has reported positive interim data from the Phase II segment of its HexAgon study assessing INBRX-106 in treatment-naïve, PD-L1 positive metastatic or unresectable recurrent HNSCC.

The post Inhibrx announces positive interim results from HexAgon trial appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.